4498-32-2
Chemical Structure
Dibenzepine
- CAS No.: 4498-32-2
- Formula:C18H21N3O
- Molecular Weight:295.39
IUPAC Name: 10-(2-(dimethylamino)ethyl)-5-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
InChIKey: QPGGEKPRGVJKQB-UHFFFAOYSA-N
SMILES: O=C1C=2C=CC=CC2N(C=3C=CC=CC3N1CCN(C)C)C
Biological Activity: Dibenzepine is a blood-brain barrier permeable ligand of the histamine H1 receptor (Histamine H1 Receptor), with a Ki value of 0.02 μM. Dibenzepine exhibits varying degrees of affinity for multiple serotonin receptors and dopamine receptors. Dibenzepine can be used in research related to depression, schizophrenia, dementia, and non-specific agitation[1][2][3][4][5][6][7][8][9][10].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Dibenzepine | Dibenzepine is a blood-brain barrier permeable ligand of the histamine H1 receptor (Histamine H1 Receptor), with a Ki value of 0.02 μM. Dibenzepine exhibits varying degrees of affinity for multiple serotonin receptors and dopamine receptors. Dibenzepine can be used in research related to depression, schizophrenia, dementia, and non-specific agitation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dibenzepine-d3 | Dibenzepine-d3 is the deuterated-labeled Dibenzepine (HY-12391). Dibenzepine is a blood-brain barrier permeable ligand of the histamine H1 receptor (Histamine H1 Receptor), with a Ki value of 0.02 μM. Dibenzepine exhibits varying degrees of affinity for multiple serotonin receptors and dopamine receptors. Dibenzepine can be used in research related to depression, schizophrenia, dementia, and non-specific agitation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Bieszczad B, et al. Synthesis, crystal structure and biological activity of novel analogues of tricyclic drugs. Bioorganic & medicinal chemistry letters. 2020 Nov 01;30(21):127493.
- [2]. Bieszczad B, et al. Synthesis, crystal structure and biological activity of novel analogues of tricyclic drugs. Bioorganic & medicinal chemistry letters. 2020 Nov 01;30(21):127493.
- [3]. De Leenheer A, et al. Improved method for determining dibenzepine and its N-demethylated metabolites in human urine. J Pharm Sci. 1973 Jan;62(1):31-6.
- [4]. Brochon R, et al. The detection and determination of dibenzepine and its metabolites in autopsy material. Arch Toxikol. 1969;24(4):249-59.
- [5]. Christensen H, et al. Dibenzepine and its metabolites in blood, muscle, liver, vitreous body and urine from fatal poisoning. Acta Pharmacol Toxicol (Copenh). 1975 Nov;37(5):393-401.
- [6]. Bonnichsen R, et al. Determination of dibenzepine in autopsy material. Z Rechtsmed. 1971;68(5):253-60.
- [7]. Schlicht HJ, et al. Gas chromatographic determination of dibenzepine and its basic metabolites in biological material. J Chromatogr. 1978 Dec 11;166(2):599-603.
- [8]. Langslet A, et al. Effects of dibenzepine and imipramine on the isolated rat heart. Eur J Pharmacol. 1971 May;14(4):333-9. [Content Brief]
- [9]. van der Meer JW, et al. Abstract!. The Netherlands journal of medicine. 2002 Dec;60(11):418. [Content Brief]
- [10]. Jadrić R, et al. Comparison of trazodone, diazepame and dibenzepine influences on rat brain beta-endorphins content. Bosnian journal of basic medical sciences. 2007 Aug;7(3):222-5.
